Anticancer Drug DevelopmentAccelerating Oncology Drug Development
We employ a consultative approach that draws upon our world-class scientific expertise and proprietary technologies to address issues such as:
Which cancer indications will respond to your drug candidate?
Will drug resistance be an issue?
What is the mechanism of action?
Will your drug candidate interact with other drugs?
What are likely to be the most responsive patient groups?
To address these issues, in addition to offering standard ADMET screens, we have developed a range of proprietary and predictive oncology-focused tools. We provide services and expertise on a fee-for-service basis, and our proprietary models are available to licence.  Download the Oncology brochure here
Toxicity reporter cell lines.
In vitro models for the rapid assessment of mechanisms of toxicity (and efficacy in oncology). Specific gene promoters associated with toxicity / anti-cancer activity have been linked to biomarker reporter systems. These models provide a more rapid & cost effective means to assess modes of toxicology and/or anti-cancer activity during hit screening.
In vivo screening PK studies.
Small, cost effective PK studies, where multisampling techniques in mouse or rat mean compound and animal use is minimised.
The HRN™ mouse.
A unique mouse model with no hepatic CYP450 activity, that can be used to determine ADME, PK and efficacy in the absence of confounding first-pass metabolism.
Microarray services.
Are you hitting the desired target? Does your compound elicit the desired mechanism of action? Are there off-target effects that should concern you? As the longest-standing Agilent-accredited microarray service provider in the UK, we supply the flexibility and expertise you require from your array service partner.
|
